Casopitant
From Wikipedia, the free encyclopedia
Casopitant (trade names Rezonic (US), Zunrisa (EU)) is an neurokinin 1 (NK1) receptor antagonist undergoing research for the treatment of chemotherapy-induced nausea and vomiting (CINV).[1] It is currently under development by GlaxoSmithKline (GSK).
In July 2008, the company filed a marketing authorisation application with the European Medicines Agency. The application was withdrawn in September 2009 because GSK decided that further safety assessment was necessary.[2]
[edit] See also
[edit] References
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Serotonin modulators and stimulators (SMSs)
|
|
|
|
Others
|
|
|
|
|
|
|
|
|
|
|
|
Nonselective
|
|
|
|
MAOA-Selective
|
|
|
|
MAOB-Selective
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cholecystokinin |
|
|
| CRH |
|
|
| Galanin |
|
|
| Ghrelin |
|
|
| MCH |
|
|
| Melanocortin |
|
|
| Neuropeptide S |
|
|
| Neuropeptide Y |
|
|
| Neurotensin |
|
|
| Opioid |
|
|
| Orexin |
|
|
| Oxytocin |
|
|
| Tachykinin |
|
|
- Agonists: Substance P
Antagonists: Aprepitant
- Befetupitant
- Casopitant
- CI-1021
- CP-96,345
- CP-99,994
- CP-122,721
- Dapitant
- Ezlopitant
- FK-888
- Fosaprepitant
- GR-203,040
- GW-597,599
- HSP-117
- L-733,060
- L-741,671
- L-743,310
- L-758,298
- Lanepitant
- LY-306,740
- Maropitant
- Netupitant
- NKP-608
- Nolpitantium
- Orvepitant
- RP-67,580
- SDZ NKT 343
- Vestipitant
- Vofopitant
|
|
|
|
|
|
|
|
|
|
|
| Vasopressin |
|
|
(what is this?) (verify)
